BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
First-In-Class Drug’s List Price Is $89,500 Per Year
Executive Summary
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
You may also be interested in...
Future BMS CEO Boerner Pleas For Patience As New Products Build Momentum
Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.
BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones
Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.
Cytokinetics To Move On From Omecamtiv After FDA’s Complete Response Letter
Company said it will not conduct the additional Phase III trial recommended by the US FDA. Instead, it will focus on its cardiac myosin inhibitor, aficamten, and look for partners to take omecamtiv forward.